Rivastigmine Film, Extended Release
Brand names: Rivastigmine
Category: Neurology
FDA status: To Be Discontinued · Last FDA update: Sep 18, 2026 · First posted: Sep 18, 2026 · 1 manufacturers, 1 listed presentations
As of Sep 18, 2026, the FDA lists Rivastigmine Film, Extended Release as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Rivastigmine, Film, Extended Release, 4.6 mg/24 h (NDC 0378-9070-93) NDC 0378-9070-93 |
Mylan Pharmaceuticals Inc., a Viatris Company | Not specified | Discontinuation of the manufacture of the drug. |
Related medications in shortage
Other Neurology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Rivastigmine Film, Extended Release (FDA data as of Sep 18, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Rivastigmine Film, Extended Release. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/rivastigmine-film-extended-release.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).